The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•29 April 2026•

1 min read

enVVeno Medical Secures FDA Approval for Pivotal Non-Surgical Venous Valve Study

Key Facts

1enVVeno Medical received the first-ever FDA IDE approval for a U.S. pivotal study of a non-surgical replacement venous valve, the enVVe System.

2The company has approximately $25 million in cash and investments, sufficient to fund operations into Q3 2027.

enVVeno Medical announced it has received a landmark Investigational Device Exemption (IDE) approval from the U.S. FDA to initiate a pivotal study for its enVVe System. This marks the first-ever U.S. clinical study for a non-surgical replacement venous valve designed to treat Chronic Venous Insufficiency (CVI). The TAVVE study aims to address a significant unmet clinical need for approximately 3 million patients suffering from severe deep CVI. Financially, the company reported holding approximately $25 million in cash and investments. Management stated that these reserves are sufficient to fund ongoing operations through the third quarter of 2027. This regulatory milestone positions the company to target a multi-billion dollar market within the biotech sector.